FyoniBio® the service branch of Glycotop


With beginning of 2021 Glycotope will offer its Contract Development Organization (CDO) and Clinical Lab services under the brand name FyoniBio®, the service branch of Glycotope.

With 20 years of history in biopharma development FyoniBio® is in a…


Genetic factors influencing the course of a SARS-CoV-2 infection

Epidemiologic investigation of peptide signatures, immunity, genetic predisposition, and alterations in SARS-CoV-2 (EPI-Dx)


ProBioGen licenses GlymaxX® Technology to Sanofi

Enhancement of Target Cell Killing for Innovative Therapies


New cancer-fighting immunotherapy enters clinical trials

Researchers from the MDC and Charité have developed a new gene therapy based around a special T-cell receptor that helps the immune system effectively recognize and fight cancer cells. The safety of the novel therapy is now being tested on patients…


GILUPI and SCIENION announce Collaboration for the Development of Single-Cell CTC Analysis

GILUPI GmbH and SCIENION AG announced on March 18that the companies intend to intensify their collaboration in the field of single circulating tumor cell (CTC) analysis. CTCs are rare cells that can be found in the peripheral blood of cancer…


Early warning system for intensive care units

Life-threatening situations occur time and again in an intensive care unit. To make sure that doctors can intervene in time, a team at the German Heart Center Berlin (DHZB) has developed AI-based software that regularly evaluates all monitoring data…

Show more items